Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Savara Inc. (NASDAQ:SVRA) has received a consensus rating of “Moderate Buy” from six analysts, with five recommending a buy and one holding the stock.
• The average 1-year price target among analysts is $6.67, reflecting varied outlooks with certain firms issuing different target prices based on recent evaluations.
• Insider trading activity saw Director Richard J. Hawkins purchase 48,225 shares at an average cost of $2.04, increasing his ownership by 71.72%.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $6.6667.

Several equities research analysts have weighed in on SVRA shares. Wells Fargo & Company dropped their target price on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 28th. HC Wainwright raised their price target on Savara from $5.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, September 3rd. Evercore ISI lowered their price target on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Guggenheim reissued a "buy" rating and set a $8.00 price target (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Finally, Oppenheimer raised their price target on Savara from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, August 15th.

Savara Price Performance

Shares of NASDAQ SVRA opened at $3.72 on Monday. Savara has a 1-year low of $1.89 and a 1-year high of $4.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The business's fifty day moving average price is $2.71 and its two-hundred day moving average price is $2.71. The firm has a market capitalization of $642.96 million, a PE ratio of -7.44 and a beta of 0.56.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). On average, research analysts expect that Savara will post -0.45 EPS for the current year.

Insider Activity at Savara

In other Savara news, Director Richard J. Hawkins purchased 48,225 shares of the stock in a transaction dated Friday, June 20th. The shares were bought at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares of the company's stock, valued at approximately $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.13% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Ameriprise Financial Inc. acquired a new position in Savara during the fourth quarter worth about $37,000. Prudential Financial Inc. acquired a new position in Savara during the second quarter worth about $30,000. BNP Paribas Financial Markets grew its holdings in Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after acquiring an additional 4,626 shares during the period. May Hill Capital LLC acquired a new position in Savara during the second quarter worth about $32,000. Finally, Brevan Howard Capital Management LP acquired a new position in Savara during the second quarter worth about $33,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.